Ping Yan

Dr. Ping Yan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
FLFuxing Li
Fuxing Li
SKShan Kong
Shan Kong
KXKexin Xie
Kexin Xie
YZYulin Zhang
Yulin Zhang
PYPing Yan
Ping Yan
WZWeidong Zhao
Weidong Zhao
There is limited data on serum biomarkers in distinguishing Mycoplasma pneumoniae (MP) from Streptococcus pneumoniae (SP) and viral pneumoniae (VP) etiologies of community-acquired pneumonia (CAP). A retrospective study of inpatients diagnosed with CAP at the First Affiliated Hospital of Dali University (Dali, Yunnan, China) between January 2018 and June 2020 was conducted. The demographic, clinical and laboratory data of the patients with CAP were analyzed. Univariate analyses identified predictors for MP infections. The discriminative power of C-reactive protein (CRP), procalcitonin (PCT), CRP/PCT and CRP/PCT >350 μg/ng was assessed by area under the curve (AUC) of the receiver operating characteristic (ROC) curves. A total of 552 CAP patients, including 247 (44.7%) with MP, 152 (27.6%) with SP and 153 (27.7%) with influenza A and B viruses, were enrolled. When comparing MP with SP, cough and CRP/PCT >350 μg/ng (odds ratio [OR]) 2.88, p < .001) were predictors for MP. CRP/PCT >350 μg/ng had 76% sensitivity and 100% specificity (AUC = 0.89, p < .001, 95% confidence interval [CI]:0.81–0.94) to predict MP infections. Furthermore, similar results were again obtained when comparing MP with VP. CRP/PCT >350 μg/ng present better information (OR: 4.70; AUC = 0.92, p < .001, 87% sensitivity and 100% specificity). In addition, comparing MP and non-MP (SP and VP combined), CRP/PCT >350 μg/ng exhibited excellent performance (AUC = 0.90, 95%CI 0.83–0.95, p < .001, 76% sensitivity and 100% specificity). CRP/PCT ratio may be a potential index to distinguish MP-CAP from non-MP-CAP.

8 August 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YZYuanqi Zhao
Yuanqi Zhao
ZZZijian Zhou
Zijian Zhou
XCXiuyu Cui
Xiuyu Cui
YYYiwei Yu
Yiwei Yu
PYPing Yan
Ping Yan
WZWeidong Zhao
Weidong Zhao

10 March 2022 in PeerJ
Verified
Journal Article
Open access
PDF file
FLFuxing Li
Fuxing Li
YZYulin Zhang
Yulin Zhang
BYBocheng Yu
Bocheng Yu
ZZZihua Zhang
Zihua Zhang
YFYujuan Fan
Yujuan Fan
WZWeidong Zhao
Weidong Zhao
Background: Sepsis is a serious syndrome that is caused by immune responses dysfunction and leads to high mortality. The abilities of heat shock protein 90α (HSP90α) in assessing the diagnosis and prognosis in patients with sepsis remain ill-defined to date. We conducted a study to reveal the possible clinical applications of HSP90α as biomarker for the diagnosis and prognosis in patients with sepsis. Methods: In total, 150 patients of sepsis, 110 patients without sepsis admitted to ICU and 110 healthy subjects were involved in this study. The serum HSP90α contents, sequential organ failure assessment (SOFA) scores, procalcitonin (PCT), and short-term survival status of the participants were measured and compared. Logistic and linear regression models adjusting for potential confounders were used to examine the association of HSP90α with sepsis survival. Moreover, serum IL-1β, IL-18, MIP-3α, and ENA-78 were also determined. Finally, Spearman correlation analysis was employed to reveal a possible mechanism that HSP90α contributed to the short-term deaths. Results: Serum HSP90α levels in sepsis patients were higher than those in ICU controls and healthy controls (P < 0.001), and even increased in patients who died within 28 days (P < 0.001). Logistic and linear regression models identified HSP90α was an independent risk factors for sepsis mortality. Receiver operating characteristic (ROC) analysis displayed that HSP90α had a considerable predictive performance for sepsis outcome, with an area under curve (AUC) value up to 0.79. Survival analysis demonstrated that the mortality of sepsis individuals at 28 days was positively associated with HSP90α levels, especially the levels of HSP90α were greater than 120 ng/mL (P < 0.001). Moreover, among sepsis patients, those who died had notably elevated cytokines, IL-1β, IL-18, and chemokines, MIP-3α, ENA-78, relative to survivors. Further correlation analysis demonstrated that there was a nominally positive correlation between HSP90α and IL-1β, IL-18, and MIP-3α. Conclusion: HSP90α is of favorable clinical significance in sepsis diagnosis and prognosis, laying a foundation for future clinical applications.

24 January 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
XCXiuyu Cui
Xiuyu Cui
YHYingchun He
Yingchun He
BYBocheng Yu
Bocheng Yu
FZFangxia Zou
Fangxia Zou
JWJing Wang
Jing Wang
WZWeidong Zhao
Weidong Zhao
Background: This study aims to identify key factors influencing the severity of COVID-19 and to develop a predictive model for assessing disease severity. Methods: A retrospective analysis was conducted on 164 patients with COVID-19 admitted to the First Affiliated Hospital of Dali University from July 2022 to February 2024, and the integrity of electronic medical records and laboratory databases of all included patients was systematically reviewed. Based on established diagnostic criteria for COVID-19 severity, patients were categorized into two groups: mild/ordinary (94 cases) and severe/critical (70 cases). Lasso regression and multivariate logistic regression were employed to identify independent risk factors, and a predictive model was constructed using a column chart. Internal validation of the model was conducted with receiver operating characteristic (ROC) curves, 10-fold cross-validation and calibration curves. The clinical utility of the model was evaluated using decision curve analysis. Results: Univariate analysis revealed significant differences between the mild/ordinary and severe/critical groups in levels of IL-4, IL-6, IL-8, IL-10, IL-17, IFN-γ, WBC count, neutrophils (N), lymphocytes (L), red blood cells (RBC), hematocrit (HCT), R-CV, R-SD, CRP, PCT, DBI, AST, TP, ALB, urea, creatinine (CREA), uric acid (UA), sodium (Na), magnesium (Mg), calcium (Ca), and total cholesterol (TC) (all P < 0.05). Lasso regression identified IL-6, IL-8, IL-17, IFN-γ, N, R-CV, TP, ALB, and urea as predictive variables. Multivariate logistic regression confirmed that IL-6, IL-8, and IL-17 were independent risk factors for COVID-19 severity. The model demonstrated an area under the curve (AUC) of 0.88, with a sensitivity of 74.3% and specificity of 94.7%. The 10-fold AUCs are 0.691, 0.939, 0.657, 1.00, 0.81, 0.797, 0.75, 0.847, 0.969, and 1.00, with an average AUC of 0.856 (95% confidence interval: 0.791–0.922). The calibration curve showed strong agreement between predicted and actual values. Clinical decision curve analysis shows that the model offers optimal clinical utility, with a net benefit higher than alternative strategies when the probability threshold is between 15% and 95%. Conclusions: IL-6, IL-8, and IL-17 are identified as independent risk factors for the severity of COVID-19. The predictive model based on these factors provides a reliable tool for assessing disease severity in COVID-19 patients.